Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
|
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [1] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Marwan Ghosn
    Alain Dagher
    Fadi El-Karak
    TheJournalofBiomedicalResearch, 2015, 29 (05) : 420 - 422
  • [2] Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer
    Newling, Don W. W.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 13 - 19
  • [3] Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer
    Kanao, Kent
    Ito, Toshiki
    Takahara, Kiyoshi
    Ando, Ryosuke
    Yasui, Takahiro
    Shiroki, Ryoichi
    Miyake, Hideaki
    Sumitomo, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 1043 - 1048
  • [4] Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
    Eastham, JA
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (10): : 482 - 491
  • [5] PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME AND DISEASE RELAPSE AFTER RADIOTHERAPY FOR PROSTATE-CANCER
    POLLACK, A
    ZAGARS, GK
    KAVADI, VS
    CANCER, 1994, 74 (02) : 670 - 678
  • [6] Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Fizazi, Karim
    Rouge, Thibault de La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1602 - 1609
  • [7] Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer
    Park, Yong Hyun
    Hwang, In Sik
    Jeong, Chang Wook
    Kim, Hyeon Hoe
    Lee, Sang Eun
    Kwak, Cheol
    JOURNAL OF UROLOGY, 2009, 181 (06) : 2520 - 2524
  • [8] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [9] Prostate-Specific Antigen Doubling Time as a Predictor of Gleason Grade in Prostate Cancer
    Nowroozi, Mohammad Reza
    Zeighami, Shahryar
    Ayati, Mohsen
    Jamshidian, Hassan
    Ranjbaran, Ali Reza
    Moradi, Asaad
    Afsar, Firuzeh
    UROLOGY JOURNAL, 2009, 6 (01) : 27 - 30
  • [10] Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
    Brady-Nicholls, Renee
    Zhang, Jingsong
    Zhang, Tian
    Wang, Andrew Z.
    Butler, Robert
    Gatenby, Robert A.
    Enderling, Heiko
    NEOPLASIA, 2021, 23 (09): : 851 - 858
12345